pevonedistat (MLN4924) - Takeda
mitoxantrone - Generic mfg.
vadastuximab talirine (SGN-CD33A) - Pfizer
azacitidine - Generic mfg.
cytarabine - Generic mfg.
magrolimab (ONO-7913) - Ono Pharma, Gilead
Idhifa (enasidenib) - BMS, Servier
emavusertib (CA-4948) - Curis, Dr. Reddy’s
Recentin (cediranib) - AstraZeneca
entospletinib (GS-9973) - Kronos Bio
onvansertib (PCM-075) - Cardiff Oncology
Beleodaq (belinostat) - Aurobindo, Assertio
flotetuzumab (MGD006) - MacroGenics
eprenetapopt (APR-246) - Aprea
Tasigna (nilotinib) - Novartis, Inhibikase
Farydak (panobinostat) - Secura Bio
alvocidib (DSP-2033) - Sumitomo Pharma
https://library.ehaweb.org/eha/2025/eha2025-congress/4161658/moazzam.shahzad.efficacy.and.outcomes.of.novel.therapeutic.agents.as.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5845%2Afeatured%3D19595
 
Moazzam Shahzad; Muhammad Fareed Khalid; Hafiz Javed; Mamoon Ahmed; Zeeshan Sattar; Ramiro Garzon; Zaker Schwabkey
 
May 16, 2025
 
Prev Next